Physician profile
Nikolas Krishna
NPI 1205132792
$123,990.14
in general payments reported to CMS, 2019-2025
32 companies · $6,074 in 2025
The $6,074 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,995 · 2021: $7,811 · 2022: $21K · 2023: $57K · 2024: $14K · 2025: $6,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $7,856 · Food and Beverage: $5,770 · Honoraria: $4,900 · Education: $37.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,790.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,455.00 |
| Travel and Lodging | $7,855.68 |
| Food and Beverage | $5,769.75 |
| Honoraria | $4,900.00 |
| Education | $37.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $47,311.82 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,813.07 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $15,430.17 | 2019-2025 | |
| Scpharmaceuticals INC. | $9,496.15 | 2023-2025 | |
| Lilly USA, LLC | $7,020.00 | 2022-2024 | Jardiance |
| Vifor Pharma, INC. | $6,851.29 | 2019-2022 | |
| Pfizer INC. | $3,694.24 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $658.66 | 2021-2025 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $438.60 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $297.81 | 2022-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $230.19 | 2019-2025 | Camzyos |
| Abiomed | $221.29 | 2020-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $217.78 | 2021-2025 | Lifevest |
| Cvrx, INC. | $206.49 | 2021-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $158.44 | 2021-2025 | Amvuttra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $155.48 | 2019-2021 | |
| Amgen INC. | $143.96 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.48 | 2024-2025 | |
| Edwards Lifesciences Corporation | $78.61 | 2021-2022 | |
| Bridgebio Pharma, INC. | $72.40 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $61.45 | 2020-2021 | |
| Daiichi Sankyo INC. | $55.18 | 2024-2025 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $53.18 | 2022 | |
| Philips North America LLC | $43.25 | 2020 | |
| Novo Nordisk INC | $34.20 | 2023-2024 | Ozempic, Rybelsus |
| Kestra Medical Technology Services, INC. | $33.09 | 2022 | |
| American Regent | $28.29 | 2023 | Injectafer |
| Lantheus Medical Imaging, INC. | $27.97 | 2024 | |
| Sanofi-Aventis U.S. LLC | $26.50 | 2019 | |
| Amarin Pharma, INC. | $16.32 | 2020 | |
| Endotronix, INC. | $16.14 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikolas Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.